Journal
CURRENT CANCER DRUG TARGETS
Volume 11, Issue 3, Pages 332-337Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800911794519806
Keywords
Antabuse (disulfiram); multidrug resistance; angiogenesis; proteasome; cancer; non-profit drug
Categories
Funding
- Czech Science Foundation [303/08/P137]
Ask authors/readers for more resources
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a non-profit drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available